ultra-rapid-acting recombinant human insulin (BIOD-123) - Albireo
Biodel: JMP Securities Healthcare Conference (Biodel) - Jul 12, 2013 - "Primary endpoint on injection site tolerability was measured as an 100 mm Visual Analog Scale (VAS): 0 = no discomfort; 100 = worst possible discomfort; 3 = usual injection" 
P1 data Diabetes
http://investor.biodel.com/events.cfm
 
Jul 12, 2013
 
.